← Open Payments lookup

SAMUEL COLLIER: Open Payments

NPI 1508064114 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$2,188 in 33 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $2,188

Food & beverage: $1,116Travel & lodging: $1,072
CompanyPaymentsAmount
Neurocrine BioSciences, Inc.12$1,551
Boehringer Ingelheim Pharmaceuticals, Inc.1$114
Otsuka Pharmaceutical Development & Commercialization, Inc.1$113
E.R. Squibb & Sons, L.L.C.5$98
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)4$93
Janssen Pharmaceuticals, Inc3$75
Otsuka America Pharmaceutical, Inc.3$67
Teva Pharmaceuticals USA, Inc.3$60
Vanda Pharmaceuticals Inc.1$19

Products named: REXULTI, COBENFY, CAPLYTA, INVEGA SUSTENNA, AUSTEDO XR, INGREZZA, FANAPT.

Industry payments across TX — which companies pay providers there.